Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Growth Hormone Deficiency (GHD)

In brief

The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.

Key facts

Study ID

NCT06948214

Run by

Lumos Pharma

People needed

150

Starts

2026-05-20

Expected to finish

2028-01-01

Last updated by the study team

2026-08-06

Who can join

Age: 3 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must be naïve to treatment and prepubertal
• Subjects must have a maximal GH response of < 10 ng/mL from 2 prior GH stimulation tests conducted within the preceding 12 months
• Impaired height defined as ≥ 2.0 standard deviations (SDs) below the mean height for chronological age and sex
• Morning or random cortisol level of ≥ 7.0 μg/dL
• ≥ 3.0 years and age ≤ 10.0 years for girls and ≤ 11.0 years for boys
• Baseline height velocity (HV) based on ≥ 6 months of growth assessments < 25th percentile for age and sex
• Bone Age delay of ≥ 12 months compared to the chronological age
• In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative.
• Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 3 months prior to Day 1
• Baseline IGF-1 standard deviation score (SDS) ≤ -1.0

You may not qualify if…

• Any medical or genetic condition which, in the opinion of the Investigator or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment.
• Arm span to height ratio > 2 SDs below the mean for age and sex
• A medical or genetic condition that, in the opinion of the Investigator and/or MM, adds unwarranted risk to use of LUM-201
• Use of any medication that, in the opinion of the Investigator and/or MM, can independently cause short stature or limit the response to exogenous growth factors
• Current inflammatory diseases requiring systemic corticosteroid treatment for > 2 consecutive weeks within the last 3 months prior to the Screening Visit
• Use of hormone replacement therapy for any hormone deficiency other than thyroid deficiency
• Any ECG at the Screening Visit noted to have a clinically significant abnormality, as confirmed by the MM
• Any subjects suspected of having past or present intracranial tumor growth as confirmed by brain imaging prior to the Screening or Day 1 Visit
• Any subject suspected of having intracranial hypertension (IH) as confirmed by fundoscopy and other assessments
• Any subject with serum alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin > upper limit of normal (ULN)
• Suspicion of absent pituitary function as evidenced by a maximal stimulated GH ≤ 3.0 ng/mL on any prior standard of care GH stimulation test completed within 12 months
• Body weight ≤ 14.0 kg
• BMI < -2 or > +2 SDs for age and sex based on WHO standards
• Birth weight for gestational age < 3rd percentile based on WHO standards
• Treatment with medications known to be moderate or strong inhibitors or strong inducers of cytochrome P450 (CYP) 3A/4
• History of spinal, cranial, or total body irradiation
• Attention deficit hyperactivity disorder (ADHD) diagnosis

Where it is running

• Lumos Pharma Investigational Site — Birmingham, Alabama, United States (enrolling)
• Lumos Pharma Investigational Site — Madera, California, United States (enrolling)
• Lumos Pharma Investigational Site — Orange, California, United States (enrolling)
• Lumos Pharma Investigational Site — Sacramento, California, United States (enrolling)
• Lumos Pharma Investigational Site — San Diego, California, United States (enrolling)
• Lumos Pharma Investigational Site — Centennial, Colorado, United States (enrolling)
• Lumos Pharma Investigational Site — Greenwood Village, Colorado, United States (enrolling)
• Lumos Pharma Investigational Site — Washington D.C., District of Columbia, United States (enrolling)
• Lumos Pharma Investigational Site — Hollywood, Florida, United States (enrolling)
• Lumos Pharma Investigational Site — Jacksonville, Florida, United States (enrolling)
• Lumos Pharma Investigational Site — Miami, Florida, United States (enrolling)
• Lumos Pharma Investigational Site — Orlando, Florida, United States (enrolling)
• Lumos Pharma Investigational Site — Tallahassee, Florida, United States (enrolling)
• Lumos Pharma Investigational Site — Indianapolis, Indiana, United States (enrolling)
• Lumos Pharma Investigational Site — Iowa City, Iowa, United States (enrolling)
• Lumos Pharma Investigational Site — New Orleans, Louisiana, United States (enrolling)
• Lumos Pharma Investigational Site — Minneapolis, Minnesota, United States (enrolling)
• Lumos Pharma Investigational Site — Kansas City, Missouri, United States (enrolling)
• Lumos Pharma Investigational Site — Las Vegas, Nevada, United States (enrolling)
• Lumos Pharma Investigational Site — New Brunswick, New Jersey, United States (enrolling)
• Lumos Pharma Investigational Site — Staten Island, New York, United States (enrolling)
• Lumos Pharma Investigational Site — Oklahoma City, Oklahoma, United States (enrolling)
• Lumos Pharma Investigational Site — Columbia, South Carolina, United States (enrolling)
• Lumos Pharma Investigational Site — Amarillo, Texas, United States (enrolling)
• Lumos Pharma Investigational Site — Corpus Christi, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.